Opportunities are there for the taking and that is certainly what Eli Lilly (NYSE:LLY) appears to be doing in the diabetes/obesity segment. Investors obviously think that too, having been leaning
Opportunities are there for the taking and that is certainly what Eli Lilly (NYSE:LLY) appears to be doing in the diabetes/obesity segment. Investors obviously think that too, having been leaning
Anyone doubting the stock market rally has legs should just have a short conversation with Ken Fisher. The billionaire investor has kept a bullish stance for a while, swatting away
There’s an interloper in the house. Tech has been the market’s driving theme over the past year, but one stock piling on the gains has been a bit of an
Befitting a non-tech name that has managed to keep up with the AI-focused rally seen over the past year, Eli Lilly’s (NYSE:LLY) 2024 has kicked off in similar fashion to
Amongst all the Big Tech names piling on the gains in last year’s AI-driven bull market, Eli Lilly (NYSE:LLY) gave some representation for the Big Pharma camp. Last year has